Euronet's Three Tollbooths Are Priced for Demolition — The Market May Be Wrong

When a founder who has run a business for three decades — and owns $171 million of its stock — starts buying back shares at a pace that retires 5-6% of the float annually, an investor should ask a simple question: does the person with the best information about this business agree with the market's assessment that it is dying? At $66.53 per share, Euronet Worldwide trades at under 10 times earnings and yields approximately 12-15% on free cash flow, depending on which year's cash generation you normalize. The market is pricing this as a melting ice cube. The founder is pricing it as a once-in-a-decade opportunity to compound his ownership. One of them is wrong.

Euronet operates three interconnected payment infrastructure businesses spanning 207 countries, built over thirty years through a combination of regulatory licensing, physical terminal deployment, and relationship-building that no competitor has replicated at comparable breadth. The EFT segment processes transactions through 56,818 ATMs and approximately 610,000 POS terminals, earning fees on cash withdrawals and — critically — dynamic currency conversion margins when international tourists opt to be charged in their home currency. The epay segment connects over a thousand content brands to consumers through 749,000 retail POS terminals, earning commissions of 5-15% on gaming gift cards, mobile top-ups, and digital content, with the gaming vertical alone representing 37% of branded payments margin in a $290 billion global market growing at a 13% annual clip. The Money Transfer segment, the largest at 42% of revenue, operates the Ria and Xe brands alongside the Dandelion B2B settlement platform that has attracted Citi, HSBC, Commonwealth Bank of Australia, and WorldFirst as partners. This is not a single-product company vulnerable to a single competitive threat — it is a diversified payment infrastructure platform where weakness in one segment can be offset by strength in another.

The moat here is genuine but narrow — and the distinction matters enormously for the investment case. Charlie Munger's test asks whether you could replicate this business with a billion dollars and a decade of effort. The honest answer is: probably not, but not because the technology is irreplicable. The barrier is the regulatory licensing across 207 countries, the physical terminal density that took thirty years to assemble, and the settlement infrastructure that pre-funds billions in working capital across dozens of currencies. A digital-native competitor like Wise can offer cheaper remittance pricing because it does not carry the overhead of physical agent networks — but it also cannot serve the immigrant construction worker in Houston who needs to hand cash to an agent on payday and have his wife collect pesos in Guadalajara within minutes. The corridors where Wise excels (high-value, digitally-savvy, developed-to-developed) are real competitive threats. The corridors where Ria dominates (low-value, cash-intensive, developed-to-emerging) are structurally different markets with different cost structures, different customer needs, and different competitive dynamics. The most encouraging evidence on this point is that Ria's digital channel grew transactions 31% in Q4 2025 while the broader Mexico remittance market declined 5% — gaining share during an industry contraction is the mark of an operator adapting, not one being disrupted.

The financial trajectory tells a compelling if imperfect story. EPS compounded from $0.42 in 2012 to $7.44 in FY2025 — an eighteen-fold increase driven by revenue growth from approximately $1.3 billion to $4.24 billion, operating margin expansion from roughly 7% to 12-13%, and share count reduction from 53 million to 42 million. Free cash flow per share went from $2.81 to $14.08 over twelve years, compounding at approximately 17% annually. The share count reduction alone — a 21% decline over the decade — converted single-digit organic growth into mid-teens per-share compounding, demonstrating the mechanical power of disciplined buybacks funded by genuine cash generation rather than debt.

The honest concerns deserve equal weight. ROIC peaked at 15-16% in 2018-2019 and has recovered only to approximately 10% post-COVID, despite revenue surpassing 2019 levels by over 45%. That gap — more revenue, lower capital efficiency — persisted for four consecutive years, suggesting something structural may have shifted in the business economics. The $2.245 billion receivables balance, representing over 50% of annual revenue, reveals that this is not the asset-light tollbooth the narrative implies — it is a settlement-intensive infrastructure business that ties up billions in working capital to operate across dozens of currencies and time zones. Most concerning, FY2025 operating cash flow fell 24% to $560 million despite revenue and net income both growing. The most benign explanation is year-end settlement timing; the most concerning is that the business now requires more working capital per dollar of revenue than it did before COVID, permanently compressing the free cash flow yield that makes the valuation case so attractive. First-half 2026 operating cash flow — expected by late July or August — will resolve this question. Above $350 million cumulative, the timing explanation holds. Significantly below that, the structural capital intensity thesis gains credibility.

The management signals from the Q4 2025 earnings call are mixed in revealing ways. CEO Brown acknowledged "one of the more challenging operating environments that we have faced in some time" — candid language for a founder who has navigated the 2008 crisis, Greek instability, Indian demonetization, and COVID. But he guided for 10-15% adjusted EPS growth in 2026, and specifically highlighted the EFT segment's transformation from ATM-centric to payment infrastructure as "an important point" — deliberate emphasis suggesting management views this pivot as the key narrative investors should internalize. The merchant acquiring business within EFT grew adjusted EBITDA 32% in 2025, the Credia Bank partnership adds 20,000 merchants, and the CoreCard acquisition has already won Bilt 2.0 and Coinbase as clients. These are concrete proof points, not aspirational slides. What management is NOT saying, however, is equally important: no Dandelion revenue or volume figures have been disclosed despite multiple quarters of partner announcements, and no succession plan has been articulated for a 30-year founder-CEO whose institutional knowledge spans regulatory relationships across 207 countries.

At $66.53, the market is essentially pricing in permanent growth stagnation — something like 1-2% perpetual free cash flow growth forever — for a business that has compounded at 10-17% across multiple metrics for over a decade and whose CEO just guided for 10-15% growth. That is an extraordinary gap between market-implied expectations and management's stated trajectory. Even applying a conservative 13x multiple to FY2025 EPS of $7.44 produces approximately $97 — a 45% premium to the current price. Cross-checked through owner earnings — free cash flow minus stock compensation — of roughly $9 per share at 10-11x yields $90-99. The EV/EBITDA of approximately 5.8x on FY2025 EBITDA of $668 million is well below the 10-15x range where mid-cap payment processors typically trade.

The bottom line is straightforward: this is a narrow-moat business with a genuine and testing competitive environment, run by an aligned founder-CEO buying back shares aggressively at a valuation that prices in catastrophe. The risk is real — Wise is repricing remittance corridors, European DCC regulation could compress ATM margins overnight, and the post-COVID ROIC plateau raises honest questions about capital efficiency. But the price already reflects those risks and then some. If Euronet merely sustains $7-8 in EPS while Brown continues retiring 5-6% of the float annually, the stock compounds at mid-teens annualized returns from $66.53 without any multiple expansion, margin recovery, or Dandelion revenue materializing. Those are the kind of odds that patient capital was designed to exploit.